Mergers & Acquisitions - Licensing

Filter

Current filters:

Licensing

Popular Filters

28 to 52 of 1738 results

Otsuka acquires certain Dacogen and E7727 rights from Eisai

01-04-2014

Otsuka Pharmaceutical has reached an agreement with the US subsidiary of fellow Japanese drugmaker Eisai…

DacogenE7727EisaiLicensingOncologyOtsukaPharmaceutical

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

Johnson & Johnson accepts $4 billion offer for Ortho-Clinical Diagnostics

01-04-2014

US health care giant Johnson & Johnson revealed yesterday that it has accepted the binding offer from…

Johnson & JohnsonMergers & AcquisitionsPharmaceutical

Clinigen gains rights to SpePharm’s Savene

Clinigen gains rights to SpePharm’s Savene

31-03-2014

The UK’s specialty pharma firm Clinigen Group says it has acquired rights to Savene (dexrazoxane) from…

Clinigen GroupGlobalLicensingNorgineOncologyPharmaceuticalSaveneSpePharma

Tiziana Pharma plans listing via reverse takeover

Tiziana Pharma plans listing via reverse takeover

31-03-2014

Tiziana Pharma, a recently-established UK biotech company that has licensed technology for a potential…

BiotechnologyMergers & AcquisitionsOncologyTiziana

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

Lansen Pharma acquires China rights to Novartis’ Sicorten Plus

31-03-2014

Hong Kong-listed Lansen Pharmaceutical has acquired the pharmaceutical product, marketed and sold in…

Asia-PacificChinaDermatologicalsLansen PharmaceuticalMergers & AcquisitionsNovartisPharmaceuticalSicorten

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

GSK acquires remaining 30% of its Indonesian Consumer Healthcare business

28-03-2014

US pharma giant GlaxoSmithKline has acquired full ownership of its Indonesian Consumer Healthcare business…

Asia-PacificGlaxoSmithKlineIndonesiaMergers & AcquisitionsPharmaceuticalProduction

Robust 2013 for biotech licensing deals; average up-front payment jump 60%

28-03-2014

Biotech licensing deals have been trending up markedly in recent months, according to the new installment…

BiotechnologyFinancialLicensing

Baxter to split, creating two separate health care companies

Baxter to split, creating two separate health care companies

28-03-2014

News that USA-based Baxter International plans to create two separate, independent global health care…

Baxter InternationalManagementMergers & AcquisitionsPharmaceutical

Glenmark gets $4 million milestone in Forest collaboration

Glenmark gets $4 million milestone in Forest collaboration

27-03-2014

Indian drugmaker Glenmark Pharmaceuticals has informed the Stock Exchange today that the company through…

FinancialForest LaboratoriesGlenmark PharmaceuticalsInflammatory diseasesLicensingPharmaceutical

India’s Lupin acquires Laboratorios Grin to enter Latin American market

27-03-2014

Indian pharma major Lupin has acquired a 100% equity stake in Mexican company Laboratorios Grin, subject…

IndiaLaboratorios GrinLupinMergers & AcquisitionsMexicoOphthalmicsPharmaceutical

Biotie to regain global rights to tozadenant from UCB

Biotie to regain global rights to tozadenant from UCB

26-03-2014

Finland-based Biotie Therapies says that partner Belgium-based drugmaker, following a portfolio review,…

BiotechnologyBiotie TherapiesLicensingNeurologicaltozadenantUCB

AstraZeneca acquires full control of Japanese subsidiary

AstraZeneca acquires full control of Japanese subsidiary

26-03-2014

Anglo-Swedish drug major AstraZeneca today announced the completion of the purchase of Sumitomo Chemical’s…

Asia-PacificAstraZenecaJapanMergers & AcquisitionsPharmaceutical

SIFI and NovaMedica link up to market eye care products in Russia

SIFI and NovaMedica link up to market eye care products in Russia

26-03-2014

Italian developer of innovative eye care solutions SIFI SpA Russian pharmaceutical company NovaMedica…

Eastern EuropeLicensingMarkets & MarketingNovaMedicaOphthalmicsPharmaceuticalRussiaSIFI SpA

Xenon and Genentech establish new pain discovery collaboration

26-03-2014

Privately-held US biotech firm Xenon Pharmaceuticals has established a new collaboration with Swiss drug…

BiotechnologyGenentechLicensingNeurologicalResearchRocheXenon Pharmaceuticals

AMRI to acquire Cedarburg Pharmaceuticals in $41 million deal

24-03-2014

Albany Molecular Research, a USA-based contract research and manufacturing organization, has signed a…

Albany Molecular ResearchCedarburg PharmaFinancialGenericsMergers & Acquisitions

Horizon Pharma in reverse merger to acquire Vidara for ~$660 million

Horizon Pharma in reverse merger to acquire Vidara for ~$660 million

20-03-2014

USA-based Horizon Pharma and privately-held, Ireland-based, Vidara Therapeutics International have entered…

Horizon PharmaMergers & AcquisitionsPharmaceuticalVidara Therapeutics International

BioAlliance Pharma licenses Sitavig to Innocutis in North America

19-03-2014

French drug developer BioAlliance Pharma has executed a licensing accord with the USA’s Innocutis Holdings…

Anti-viralsBioAlliance PharmaBiotechnologyInnocutis HoldingsLicensingNorth AmericaSitavig

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

Astellas and Daiichi Sankyo share 400,000 compounds in research agreement

19-03-2014

Japanese drug majors Astellas Pharma and Daiichi Sankyo will form a compound library sharing partnership…

Astellas PharmaDaiichi SankyoJapanLicensingPharmaceuticalResearch

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

Sanofi Pasteur inks deal with Korea’s SK Chemical on vaccines

19-03-2014

In a second collaboration in less than a month, Sanofi Pasteur, the vaccines division of French drug…

Asia-PacificLicensingPharmaceuticalResearchSanofiSanofi PasteurSK ChemicalVaccines

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

Five Prime rockets on immuno-oncology deal with Bristol-Myers Squibb

17-03-2014

Shares of Five Prime Therapeutics leapt 15% to $21.48 in early trading, after the company said it has…

Bristol-Myers SquibbFive Prime TherapeuticsLicensingMergers & AcquisitionsOncologyPharmaceutical

28 to 52 of 1738 results

Back to top